Archive · 12 Aug 2025
Indian Firm Approved to Make Bladder Cancer Drug
Imagine a medicine that can help people with a specific type of bladder cancer.
A company in India got permission to make this medicine called erdafitinib.
It works by stopping the cancer cells from growing quickly.
This medicine is for people whose cancer has not responded to chemotherapy.
The government said it was okay for the company to start selling this medicine sooner, but they have to do another study later to make sure it's safe and works well.
Doctors think this is good news because it gives patients a new way to fight the cancer.
Indian drug advisory panel approved Natco Pharma to manufacture and sell erdafitinib tablets for bladder cancer.
The approval includes a waiver for local third-phase clinical trials but requires a post-launch fourth-phase study.
Erdafitinib is a targeted therapy inhibiting the FGFR, a key driver of rapid tumor growth in certain bladder cancers.
The drug is approved for adults with advanced or metastatic bladder cancer with specific FGFR3 gene changes.
Oncologists anticipate the drug will benefit patients with advanced bladder cancer not responding to chemotherapy.
- Who
- Natco Pharma and the Indian drug advisory panel.
- What
- Approval for Natco Pharma to manufacture and market erdafitinib for bladder cancer treatment in India.
- When
- Approval given in July 2024, following the FDA approval in January 2024.
- Where
- India
- Why
- To address the unmet medical need for targeted bladder cancer treatment in India.
Traditional Drug Approval Process
Expedited Approval Process
Clinical Trials
Traditional Drug Approval Process
Requires extensive clinical trials for patient safety and efficacy.
Expedited Approval Process
Allows for quicker access to potentially life-saving medication, especially when there is an unmet medical need.
- Drug Name
- Erdafitinib
- Brand Name
- Balversa
- Target
- FGFR protein
- Indication
- Advanced bladder cancer with specific gene changes
- Manufacturer
- Natco Pharma
- FDA Approval Date
- January 19, 2024